JP2019537570A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019537570A5 JP2019537570A5 JP2019520525A JP2019520525A JP2019537570A5 JP 2019537570 A5 JP2019537570 A5 JP 2019537570A5 JP 2019520525 A JP2019520525 A JP 2019520525A JP 2019520525 A JP2019520525 A JP 2019520525A JP 2019537570 A5 JP2019537570 A5 JP 2019537570A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound
- formula
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- WDHOIABIERMLGY-CMJOXMDJSA-N N-[1-(3-fluoropropyl)azetidin-3-yl]-6-[(6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-3,6,8,9-tetrahydropyrazolo[4,3-f]isoquinolin-6-yl]pyridin-3-amine Chemical compound FCCCN1CC(C1)NC=1C=NC(=CC=1)[C@H]1N([C@@H](CC2=C3C(=CC=C12)NN=C3)C)CC(F)(F)F WDHOIABIERMLGY-CMJOXMDJSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 201000010255 female reproductive organ cancer Diseases 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 125000003566 oxetanyl group Chemical group 0.000 description 2
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662411799P | 2016-10-24 | 2016-10-24 | |
| US62/411,799 | 2016-10-24 | ||
| US201662435159P | 2016-12-16 | 2016-12-16 | |
| US62/435,159 | 2016-12-16 | ||
| PCT/EP2017/076191 WO2018077630A1 (en) | 2016-10-24 | 2017-10-13 | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020129457A Division JP6993477B2 (ja) | 2016-10-24 | 2020-07-30 | 癌の治療において有用な６，７，８，９－テトラヒドロ－３Ｈ－ピラゾロ［４，３－ｆ］イソキノリン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019537570A JP2019537570A (ja) | 2019-12-26 |
| JP2019537570A5 true JP2019537570A5 (enExample) | 2020-04-30 |
| JP6744489B2 JP6744489B2 (ja) | 2020-08-19 |
Family
ID=60083331
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520525A Active JP6744489B2 (ja) | 2016-10-24 | 2017-10-13 | 癌の治療において有用な６，７，８，９−テトラヒドロ−３Ｈ−ピラゾロ［４，３−ｆ］イソキノリン誘導体 |
| JP2020129457A Active JP6993477B2 (ja) | 2016-10-24 | 2020-07-30 | 癌の治療において有用な６，７，８，９－テトラヒドロ－３Ｈ－ピラゾロ［４，３－ｆ］イソキノリン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020129457A Active JP6993477B2 (ja) | 2016-10-24 | 2020-07-30 | 癌の治療において有用な６，７，８，９－テトラヒドロ－３Ｈ－ピラゾロ［４，３－ｆ］イソキノリン誘導体 |
Country Status (37)
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3355884T3 (pl) | 2015-10-01 | 2021-11-29 | Olema Pharmaceuticals, Inc. | Tetrahydro-1H-pirydo[3,4-b]indolowe leki antyestrogenowe |
| US9969732B2 (en) * | 2016-04-08 | 2018-05-15 | Genentech, Inc. | Tetrahydroisoquinoline estrogen receptor modulators and uses thereof |
| TW201803870A (zh) | 2016-04-20 | 2018-02-01 | 阿斯特捷利康公司 | 化學化合物 |
| US10149839B2 (en) | 2016-07-25 | 2018-12-11 | Astrazeneca Ab | Chemical compounds |
| SG11201903182XA (en) | 2016-10-24 | 2019-05-30 | Astrazeneca Ab | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer |
| TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物 |
| SI3555097T1 (sl) | 2016-12-16 | 2022-09-30 | Janssen Pharmaceutica Nv | Imidazo(4,5-d)pirolo(2,3-b)piridinske spojine kot zaviralci janus kinaz |
| JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
| LT3494116T (lt) | 2017-01-30 | 2020-01-10 | Astrazeneca Ab | Estrogeno receptorių moduliatoriai |
| WO2019002441A1 (en) * | 2017-06-29 | 2019-01-03 | Astrazeneca Ab | CHEMICAL COMPOUNDS |
| WO2019002442A1 (en) * | 2017-06-29 | 2019-01-03 | Astrazeneca Ab | CHEMICAL COMPOUNDS |
| JP7113542B2 (ja) | 2017-11-14 | 2022-08-05 | カインド ファーマシューティカル | 複素環式化合物及びその医学的応用 |
| TW202016110A (zh) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Ｊａｋ激酶家族之小分子抑制劑 |
| CN119552120A (zh) | 2018-06-15 | 2025-03-04 | 里亚塔医药公司 | 用于抑制IL-17和RORγ的吡唑和咪唑化合物 |
| EP3810141A1 (en) | 2018-06-20 | 2021-04-28 | Reata Pharmaceuticals, Inc. | Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith |
| EP3837548A2 (en) | 2018-08-17 | 2021-06-23 | F. Hoffmann-La Roche AG | Diagnostic and therapeutic methods for the treatment of breast cancer |
| CN109053524A (zh) * | 2018-09-11 | 2018-12-21 | 山东谛爱生物技术有限公司 | 一种N-Boc-3-羟基氮杂环丁烷的制备方法 |
| AU2020311337A1 (en) | 2019-07-07 | 2022-01-20 | Olema Pharmaceuticals, Inc. | Regimens of estrogen receptor antagonists |
| MX2022007629A (es) * | 2019-12-20 | 2022-08-16 | Recurium Ip Holdings Llc | Combinaciones. |
| US12428428B2 (en) * | 2020-01-10 | 2025-09-30 | Jiangsu Hengrui Medicine Co., Ltd. | Tricyclic tetrahydroisoquinoline derivative, preparation method therefor and application thereof in medicine |
| EP4138834A1 (en) | 2020-04-24 | 2023-03-01 | Astrazeneca AB | Dosage regimen for the treatment of cancer |
| PH12022552755A1 (en) * | 2020-04-24 | 2024-03-25 | Astrazeneca Ab | Pharmaceutical formulations |
| US20230348459A1 (en) * | 2020-05-15 | 2023-11-02 | Simcere Pharmaceutical Co., Ltd. | Pyrrolidine compound and use thereof |
| WO2021249533A1 (zh) * | 2020-06-12 | 2021-12-16 | 江苏先声药业有限公司 | 雌激素受体调节剂化合物及其用途 |
| US12415799B2 (en) | 2020-06-28 | 2025-09-16 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | Indazole-fused cyclic compound |
| CN114105977B (zh) * | 2020-08-28 | 2023-09-01 | 先声再明医药有限公司 | 雌激素受体调节剂化合物及其用途 |
| KR20220107752A (ko) | 2021-01-26 | 2022-08-02 | 충북대학교 산학협력단 | 피라졸로퀴놀린 유도체 및 이의 항암제로서의 용도 |
| WO2022166980A1 (zh) * | 2021-02-08 | 2022-08-11 | 贝达药业股份有限公司 | 杂芳基并哌啶类衍生物及其药物组合物和应用 |
| MX2023010642A (es) | 2021-03-11 | 2023-11-28 | Janssen Pharmaceutica Nv | Lorpucitinib para uso en el tratamiento de trastornos mediados por jak. |
| US12410155B2 (en) | 2021-12-28 | 2025-09-09 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | Salt form and crystal form of tetrahydrocyclohepta indazole compound |
| EP4604957A1 (en) | 2022-10-17 | 2025-08-27 | Astrazeneca AB | Combinations of a serd for the treatment of cancer |
| JP2025539034A (ja) | 2022-11-11 | 2025-12-03 | アストラゼネカ・アクチエボラーグ | 癌の治療のための併用療法 |
| US20240180893A1 (en) | 2022-11-17 | 2024-06-06 | Astrazeneca Ab | Methods of treatment of breast cancer |
| TW202508573A (zh) | 2023-05-11 | 2025-03-01 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合療法 |
| WO2025175249A1 (en) * | 2024-02-14 | 2025-08-21 | Olema Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| ZA200301813B (en) | 2000-08-10 | 2004-06-22 | Pharmacia Italia Spa | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them. |
| CN102030750A (zh) | 2005-03-22 | 2011-04-27 | 阿斯利康(瑞典)有限公司 | 用作CB1受体配体的新四氢-1H-吡啶并[4,3-b]吲哚衍生物 |
| FR2884252B1 (fr) | 2005-04-08 | 2007-05-18 | Aventis Pharma Sa | Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90 |
| AR058223A1 (es) | 2005-11-25 | 2008-01-23 | Palau Pharma Sa | Un comuesto de derivados de pirazoloisoquinolina, un procedimiento para l a preparacion de dicho compuesto y una composicion farmaceutica que comprende dicho compuesto |
| EP2223925A1 (en) | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| PL2434891T3 (pl) | 2009-05-27 | 2020-12-28 | Ptc Therapeutics, Inc. | Sposoby leczenia nowotworu złośliwego i stanów nienowotworowych |
| WO2010138695A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating neurofibromatosis |
| WO2010138659A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating brain tumors |
| SI2580210T1 (sl) | 2010-06-10 | 2017-08-31 | Seragon Pharmaceuticals, Inc. | Modulatorji estrogenskega receptorja in njihove uporabe |
| WO2011159769A2 (en) | 2010-06-17 | 2011-12-22 | Aragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| ES2586908T3 (es) | 2010-12-24 | 2016-10-19 | Merck Sharp & Dohme B.V. | Derivados de azetidina N-sustituidos |
| CN104114551B (zh) | 2011-12-14 | 2017-01-18 | 塞拉根制药公司 | 氟化雌激素受体调节剂及其用途 |
| LT3004090T (lt) | 2013-05-28 | 2018-01-10 | Astrazeneca Ab | Cheminiai junginiai |
| RU2015152171A (ru) | 2013-06-19 | 2017-07-25 | Серагон Фармасьютикалз, Инк. | Азетидиновые модуляторы эстрогеновых рецепторов и их применения |
| WO2014205138A1 (en) | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulator and uses thereof |
| WO2015092634A1 (en) | 2013-12-16 | 2015-06-25 | Novartis Ag | 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders |
| WO2016097073A1 (en) | 2014-12-18 | 2016-06-23 | F. Hoffmann-La Roche Ag | Derivatives of 2,3-diphenylchromene useful for the treatment of cancer |
| IL301960B2 (en) | 2014-12-18 | 2024-08-01 | Hoffmann La Roche | Tetrahydro-pyrido[3, 4-b]indole estrogen receptor modulators and their uses |
| CN107406424B (zh) | 2014-12-18 | 2020-08-25 | 豪夫迈·罗氏有限公司 | 雌激素受体调节剂及其用途 |
| WO2016174551A1 (en) | 2015-04-27 | 2016-11-03 | Pfizer Inc. | Anti-estrogenic compounds |
| WO2016189011A1 (en) | 2015-05-26 | 2016-12-01 | F. Hoffmann-La Roche Ag | Heterocyclic estrogen receptor modulators and uses thereof |
| JP2018521988A (ja) * | 2015-06-16 | 2018-08-09 | ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． | ピペリジン誘導体およびその製造方法および医薬用途 |
| CN106518768B (zh) | 2015-09-15 | 2021-07-02 | 江苏恒瑞医药股份有限公司 | 丙烯酸类衍生物、其制备方法及其在医药上的应用 |
| PL3355884T3 (pl) | 2015-10-01 | 2021-11-29 | Olema Pharmaceuticals, Inc. | Tetrahydro-1H-pirydo[3,4-b]indolowe leki antyestrogenowe |
| CN108349952A (zh) | 2015-11-09 | 2018-07-31 | 豪夫迈·罗氏有限公司 | 四氢萘雌激素受体调节剂及其用途 |
| CA3011391C (en) | 2015-11-12 | 2021-02-09 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Acrylic acid derivative, preparation method and use in medicine thereof |
| JP2019503346A (ja) | 2015-12-22 | 2019-02-07 | ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． | ベンゾピペリジン誘導体、その製造方法及びその医薬用途 |
| US9969732B2 (en) * | 2016-04-08 | 2018-05-15 | Genentech, Inc. | Tetrahydroisoquinoline estrogen receptor modulators and uses thereof |
| WO2017182495A1 (en) | 2016-04-20 | 2017-10-26 | Astrazeneca Ab | Indazole derivatives that down-regulate the estrogen receptor and possess anti-cancer activity |
| TW201803870A (zh) | 2016-04-20 | 2018-02-01 | 阿斯特捷利康公司 | 化學化合物 |
| JP7064772B2 (ja) | 2016-05-06 | 2022-05-11 | ザビエル・ユニバーシティ・オブ・ルイジアナ | 選択的エストロゲン受容体ダウンレギュレーター（ｓｅｒｄｓ） |
| CN109415361B (zh) | 2016-06-29 | 2022-03-08 | 浙江海正药业股份有限公司 | 丙烯酸类衍生物及其制备方法和其在医药上的用途 |
| US10149839B2 (en) | 2016-07-25 | 2018-12-11 | Astrazeneca Ab | Chemical compounds |
| CN107814798B (zh) | 2016-09-14 | 2020-11-03 | 四川科伦博泰生物医药股份有限公司 | 3-取代丙烯酸类化合物及其制备方法和用途 |
| ES2975558T3 (es) | 2016-09-15 | 2024-07-09 | Arvinas Inc | Derivados de indol como degradantes de receptor de estrógeno |
| BR102016024814A2 (pt) | 2016-10-24 | 2018-05-08 | Aché Laboratórios Farmacêuticos S.A. | composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono |
| SG11201903182XA (en) | 2016-10-24 | 2019-05-30 | Astrazeneca Ab | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer |
| CA3045303C (en) | 2016-12-16 | 2022-05-17 | Eli Lilly And Company | 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors |
| SI3555097T1 (sl) | 2016-12-16 | 2022-09-30 | Janssen Pharmaceutica Nv | Imidazo(4,5-d)pirolo(2,3-b)piridinske spojine kot zaviralci janus kinaz |
| JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
| TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物 |
| MY195385A (en) | 2016-12-16 | 2023-01-18 | Pfizer | Glp-1 Receptor Agonists And Uses Thereof |
| US20200077658A1 (en) | 2016-12-16 | 2020-03-12 | Basf Se | Pesticidal Compounds |
| MY195588A (en) | 2017-01-30 | 2023-02-02 | Chiesi Farm Spa | Tyrosine Amide Derivatives As Rho- Kinase Inhibitors |
-
2017
- 2017-10-13 SG SG11201903182XA patent/SG11201903182XA/en unknown
- 2017-10-13 AU AU2017349797A patent/AU2017349797B2/en active Active
- 2017-10-13 CA CA3040040A patent/CA3040040A1/en active Pending
- 2017-10-13 HU HUE17783857A patent/HUE045714T2/hu unknown
- 2017-10-13 PE PE2019000845A patent/PE20191078A1/es unknown
- 2017-10-13 ES ES17783857T patent/ES2751902T3/es active Active
- 2017-10-13 EP EP19189010.2A patent/EP3640251B1/en active Active
- 2017-10-13 TW TW106135012A patent/TWI735681B/zh active
- 2017-10-13 CN CN201780064567.7A patent/CN109843888B/zh active Active
- 2017-10-13 PL PL17783857T patent/PL3433256T3/pl unknown
- 2017-10-13 ME MEP-2019-306A patent/ME03547B/me unknown
- 2017-10-13 MY MYPI2019002161A patent/MY205300A/en unknown
- 2017-10-13 US US15/782,904 patent/US10131663B2/en active Active
- 2017-10-13 CN CN202210381693.8A patent/CN114656464B/zh active Active
- 2017-10-13 SI SI201731087T patent/SI3640251T1/sl unknown
- 2017-10-13 LT LT17783857T patent/LT3433256T/lt unknown
- 2017-10-13 HU HUE19189010A patent/HUE057524T2/hu unknown
- 2017-10-13 MX MX2019004685A patent/MX382331B/es unknown
- 2017-10-13 WO PCT/EP2017/076191 patent/WO2018077630A1/en not_active Ceased
- 2017-10-13 SM SM20190602T patent/SMT201900602T1/it unknown
- 2017-10-13 HR HRP20220255TT patent/HRP20220255T1/hr unknown
- 2017-10-13 PL PL19189010T patent/PL3640251T3/pl unknown
- 2017-10-13 ES ES19189010T patent/ES2907759T3/es active Active
- 2017-10-13 DK DK19189010.2T patent/DK3640251T3/da active
- 2017-10-13 DK DK17783857T patent/DK3433256T3/da active
- 2017-10-13 SM SM20220098T patent/SMT202200098T1/it unknown
- 2017-10-13 CR CR20190204A patent/CR20190204A/es unknown
- 2017-10-13 NZ NZ753459A patent/NZ753459A/en unknown
- 2017-10-13 EP EP17783857.0A patent/EP3433256B1/en active Active
- 2017-10-13 UA UAA201905126A patent/UA125824C2/uk unknown
- 2017-10-13 LT LTEP19189010.2T patent/LT3640251T/lt unknown
- 2017-10-13 SI SI201730111T patent/SI3433256T1/sl unknown
- 2017-10-13 JP JP2019520525A patent/JP6744489B2/ja active Active
- 2017-10-13 JO JOP/2019/0090A patent/JOP20190090B1/ar active
- 2017-10-13 PT PT191890102T patent/PT3640251T/pt unknown
- 2017-10-13 RS RSP20191371 patent/RS59445B1/sr unknown
- 2017-10-13 PT PT177838570T patent/PT3433256T/pt unknown
- 2017-10-13 KR KR1020197014062A patent/KR102178692B1/ko active Active
-
2018
- 2018-10-09 US US16/155,041 patent/US10590130B2/en active Active
-
2019
- 2019-02-01 ZA ZA2019/00694A patent/ZA201900694B/en unknown
- 2019-04-16 PH PH12019500830A patent/PH12019500830A1/en unknown
- 2019-04-18 CL CL2019001077A patent/CL2019001077A1/es unknown
- 2019-04-18 CO CONC2019/0003950A patent/CO2019003950A2/es unknown
- 2019-04-22 IL IL266245A patent/IL266245B/en active IP Right Grant
- 2019-04-23 EC ECSENADI201928657A patent/ECSP19028657A/es unknown
- 2019-04-23 DO DO2019000104A patent/DOP2019000104A/es unknown
- 2019-04-24 NI NI201900039A patent/NI201900039A/es unknown
- 2019-10-24 CY CY20191101110T patent/CY1122566T1/el unknown
-
2020
- 2020-01-28 US US16/774,268 patent/US10961241B2/en active Active
- 2020-07-30 JP JP2020129457A patent/JP6993477B2/ja active Active
-
2021
- 2021-02-17 US US17/177,617 patent/US12077530B2/en active Active
-
2022
- 2022-02-23 CY CY20221100160T patent/CY1125292T1/el unknown
-
2024
- 2024-07-17 US US18/775,391 patent/US20240383895A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019537570A5 (enExample) | ||
| JP2016536286A5 (enExample) | ||
| JP2015514808A5 (enExample) | ||
| JP2016523974A5 (enExample) | ||
| JP2016534063A5 (enExample) | ||
| JP2019510832A5 (enExample) | ||
| JP2018021051A5 (enExample) | ||
| JP2009514870A5 (enExample) | ||
| JP2020500862A5 (enExample) | ||
| JP2013544846A5 (enExample) | ||
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| JP2018537535A5 (enExample) | ||
| JP2015511609A5 (enExample) | ||
| JP2016513130A5 (enExample) | ||
| JP2016501221A5 (enExample) | ||
| JP2015024998A5 (enExample) | ||
| JP2020507589A5 (enExample) | ||
| JP2020505354A5 (enExample) | ||
| JP2017526677A5 (enExample) | ||
| JP2017531619A5 (enExample) | ||
| JP2015506348A5 (enExample) | ||
| JP2015500225A5 (enExample) | ||
| JP2017517538A5 (enExample) | ||
| JP2017508782A5 (enExample) | ||
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака |